



Masimo Announces Pathway™ For The Root® Patient Monitoring And Connectivity Platform



Masimo today announced Pathway™, a feature for the [Root® Patient Monitoring and Connectivity Platform](#). Pathway provides clinicians with a way to visualize a hospital's recommended resuscitation protocol for a newborn's oxygen saturation (SpO₂) while continuously monitoring SpO₂ and pulse rate (PR) during the first ten minutes after birth. Use of Pathway is intended to help streamline clinician workflow and improve protocol adherence during this critical period. Pathway was invented by Dr. Yacov Rabi, MD, Associate Professor in the Department of Pediatrics at the Cumming School of Medicine, University of Calgary, Canada, and licensed to Masimo.

□

The International Liaison Committee on Resuscitation (American Heart Association) has developed treatment recommendations outlining time-based SpO₂ targets that reflect a healthy newborn's oxygenation during the first ten minutes after birth.¹ Current hospital practice relies on manually referencing charts or clinician recollection for adherence to protocols based on these recommendations. The ability to display local oxygen saturation targeting guidelines while still actively monitoring SpO₂ and PR via Pathway's intuitive interface is intended to help clinicians more easily adhere to their institution's resuscitation protocols. While Pathway is active, Root displays SpO₂ values alongside a visualization of the hospital-defined SpO₂ targets over time. To help clinicians track time since birth, Pathway displays an easily adjustable timer bar so that clinicians no longer need to mentally track the difference between the time of birth and the start of monitoring. Pathway can also provide hospitals with the ability to monitor and capture data involving adherence to their chosen newborn resuscitation protocols.

Dr. Rabi commented, "We created Pathway to simplify decision making during newborn resuscitation. I'm especially excited by the ability to review oxygen-saturation-targeting performance post-resuscitation as a means of supporting quality improvement and quality assurance initiatives at each institution."

Pathway's visualization on Root works in tandem with continuous SpO₂ monitoring powered by [Masimo SET® Measure-through Motion and Low Perfusion™](#) technology, which has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.² Crucially for newborn health, SET® has been shown to help clinicians reduce severe retinopathy of prematurity in neonates³ and in multiple studies, including the largest critical congenital heart disease (CCHD) study to date, to improve CCHD screening in newborns.⁴⁻⁵

Masimo Root is a powerful, versatile, and ever more expandable monitoring and connectivity hub designed for

use across the continuum of care. Root integrates an array of technologies, devices, and systems to provide multimodal monitoring and automation solutions. Root's plug-and-play expansion capabilities allow clinicians to simultaneously monitor with core Masimo technologies such as SET® pulse oximetry and rainbow® Pulse CO-Oximetry while incorporating additional modalities such as SedLine® brain function monitoring, O3® regional oximetry, NomoLine® capnography, and more – all via an easy-to-interpret, customizable display that can also be set to Vital Signs Check mode and now Pathway mode. Using Root in combination with Patient SafetyNet™ or Iris Gateway™, monitoring data can be automatically charted in electronic medical records (EMRs).

Joe Kiani, Founder and CEO of Masimo, said, "From our inception, we have been committed to improving outcomes for the youngest and most fragile patients. Our foundational SET® pulse oximetry was designed with newborns and infants in mind. These patients were never an afterthought, and we continue to seek new ways to help clinicians provide them with the best care possible. One such result is Pathway, which visualizes the reliable, accurate data harnessed by SET® in an innovative and intuitive new manner. We hope that Pathway will help clinicians more efficiently and easily keep track of a newborn's status during the critical first minutes after birth."

References

1. <https://www.ahajournals.org/doi/full/10.1161/CIR.000000000000267>.
2. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at <http://www.masimo.com>. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
3. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. *Acta Paediatr.* 2011 Feb;100(2):188-92.
4. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. *BMJ.* 2009;Jan 8;338.
5. Zhao et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. *Lancet.* 2014 Aug 30;384(9945):747-54.
6. Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. *Anesthesiology.* 2010;112(2):282-287.
7. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. *Anesthesia Patient Safety Foundation Newsletter.* Spring-Summer 2012.
8. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. *The Joint Commission Journal on Quality and Patient Safety.* 2016 Jul;42(7):293-302.
9. Estimate: Masimo data on file.
10. <http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview>.

Published on : Wed, 4 Sep 2019